DOJ Awards $4.2M Firm Fixed Price Contract for Flu Vaccine to Seqirus USA Inc
Contract Overview
Contract Amount: $4,200 ($4.2K)
Contractor: Seqirus USA Inc
Awarding Agency: Department of Justice
Start Date: 2026-03-01
End Date: 2026-09-30
Contract Duration: 213 days
Daily Burn Rate: $20/day
Competition Type: FULL AND OPEN COMPETITION
Pricing Type: FIRM FIXED PRICE
Sector: Healthcare
Official Description: FY26 B1 SEQIRUS INMATE FLU VACC SEPT 26
Place of Performance
Location: SUMMIT, UNION County, NEW JERSEY, 07901
Plain-Language Summary
Department of Justice obligated $4,199.76 to SEQIRUS USA INC for work described as: FY26 B1 SEQIRUS INMATE FLU VACC SEPT 26 Key points: 1. Contract awarded for influenza vaccine supply to federal inmates. 2. Seqirus USA Inc. is the sole awardee, indicating potential market concentration. 3. The contract value is $4.2 million for a 7-month period. 4. This procurement falls under pharmaceutical preparation manufacturing. 5. The award method is a delivery order under a larger contract.
Value Assessment
Rating: good
The contract value of $4.2 million for approximately 213 days of service appears reasonable given the specialized nature of pharmaceutical supply. Benchmarking against similar government contracts for vaccines would provide a more precise assessment.
Cost Per Unit: N/A
Competition Analysis
Competition Level: full-and-open
The contract was awarded under full and open competition, suggesting that multiple vendors had the opportunity to bid. This method generally promotes competitive pricing and ensures the government receives the best value.
Taxpayer Impact: Taxpayers benefit from competitive pricing achieved through full and open competition for essential healthcare supplies like vaccines.
Public Impact
Ensures health and safety of federal inmates through vaccination. Supports public health initiatives by preventing disease outbreaks. Provides critical pharmaceutical supplies to a government agency.
Waste & Efficiency Indicators
Waste Risk Score: 50 / 10
Warning Flags
- Potential reliance on a single supplier for critical vaccine needs.
- Fluctuations in vaccine demand could impact future contract values.
- Geographic concentration of supplier operations in New Jersey.
Positive Signals
- Awarded under full and open competition.
- Firm fixed price contract provides cost certainty.
- Addresses a critical public health need within the federal prison system.
Sector Analysis
This contract falls within the Healthcare and Pharmaceutical sector, specifically for vaccine manufacturing and distribution. Government spending in this area is crucial for public health and national security, with benchmarks varying significantly based on the specific medical product and quantity.
Small Business Impact
The data does not indicate any specific set-asides for small businesses. The awardee, Seqirus USA Inc., is a large pharmaceutical company, suggesting that small businesses were likely not primary participants in this specific procurement.
Oversight & Accountability
The award is a delivery order, implying it was issued under an existing contract vehicle. Oversight would involve monitoring performance against the delivery schedule and quality standards, as well as ensuring compliance with the firm fixed price.
Related Government Programs
- Pharmaceutical Preparation Manufacturing
- Department of Justice Contracting
- Federal Prison System / Bureau of Prisons Programs
Risk Flags
- Potential single-source dependency for critical vaccine.
- Limited duration of contract (7 months).
- Geographic concentration of supplier.
- Lack of small business participation noted.
Tags
pharmaceutical-preparation-manufacturing, department-of-justice, nj, delivery-order, under-100k
Frequently Asked Questions
What is this federal contract paying for?
Department of Justice awarded $4,199.76 to SEQIRUS USA INC. FY26 B1 SEQIRUS INMATE FLU VACC SEPT 26
Who is the contractor on this award?
The obligated recipient is SEQIRUS USA INC.
Which agency awarded this contract?
Awarding agency: Department of Justice (Federal Prison System / Bureau of Prisons).
What is the total obligated amount?
The obligated amount is $4,199.76.
What is the period of performance?
Start: 2026-03-01. End: 2026-09-30.
What is the historical pricing trend for influenza vaccines procured by the Federal Prison System?
Historical pricing data for influenza vaccines procured by the Federal Prison System is not provided in this dataset. A comprehensive analysis would require access to past contract awards for similar products, including quantities, contract types, and award dates. This would allow for trend identification and comparison against the current $4.2 million award.
What are the specific risks associated with relying on Seqirus USA Inc. for inmate influenza vaccinations?
Risks associated with relying on Seqirus USA Inc. could include supply chain disruptions, manufacturing issues, or potential price increases in future contract periods. Given their role as a key supplier, any interruption could significantly impact the health and safety of the federal inmate population, necessitating contingency planning by the Department of Justice.
How effectively does this contract address the overall influenza vaccination needs of the Federal Prison System?
This contract addresses a specific need for influenza vaccines for FY26, valued at $4.2 million. Its effectiveness in meeting the *overall* needs depends on the total inmate population, the number of vaccination sites, and whether this award covers all required doses or is part of a larger vaccination strategy. Further data on total requirement is needed for a complete assessment.
Industry Classification
NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing
Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP
Competition & Pricing
Extent Competed: FULL AND OPEN COMPETITION
Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE
Pricing Type: FIRM FIXED PRICE (J)
Evaluated Preference: NONE
Contractor Details
Address: 25 DEFOREST AVE STE 200, SUMMIT, NJ, 07901
Business Categories: Category Business, Corporate Entity Not Tax Exempt, Foreign Owned, Foreign-Owned and U.S.-Incorporated Business, Manufacturer of Goods, Not Designated a Small Business, Special Designations
Financial Breakdown
Contract Ceiling: $4,200
Exercised Options: $4,200
Current Obligation: $4,200
Contract Characteristics
Commercial Item: COMMERCIAL PRODUCTS/SERVICES
Cost or Pricing Data: NO
Parent Contract
Parent Award PIID: 36E79726D0010
IDV Type: IDC
Timeline
Start Date: 2026-03-01
Current End Date: 2026-09-30
Potential End Date: 2026-09-30 00:00:00
Last Modified: 2026-04-06
More Contracts from Seqirus USA Inc
- Purchase of H1N1 Bulk Vaccine From CSL (CAN 1993450) — $70.0M (Department of Health and Human Services)
- TAS::75 0900::TAS Clinical Studies of H1N1 REQ. Number OS15406 in Prism Arra::yes::arra — $16.3M (Department of Health and Human Services)
- Fluad Prefilled Syringes — $70.0K (Department of Veterans Affairs)
- FY 2026 FLU Vaccines - Seqirus Influenza Vaccine - to Provide Inmate Doses and Staff Doses — $3.5K (Department of Justice)
- 2026 Influenza Virus Vaccine for FCI Texarkana Inmates — $2.5K (Department of Justice)
Other Department of Justice Contracts
- Contractor Owned and Operated Existing Correctional Facility for Approximately 3,500 LOW Security Male Inmates — $794.5M (Cornell Companies, Inc.)
- Detention Services - SAN Diego — $776.9M (THE GEO Group, Inc.)
- CO: Telly Renfroe Award of NEW Task Order Base Year Initial Funding — $616.4M (AT&T Enterprises, LLC)
- TAS 151060 - Services for the Management and Operation of a Contractor-Owned, Contractor-Operated, Correctional Facility for 2,567 Beds in Adams County, Mississippi — $574.3M (Corecivic, Inc.)
- Provide Services for the Management and Operation of a Correctional Facility in Accordance With Rfp-Pcc-0014 — $568.9M (Cornell Companies, Inc.)